RGI at NSUThe strategic decision of the Board of Trustees of Royal Dames and Nova Southeastern University (NSU) with great vision in 2005 has allowed RGI to expand its horizons and become part of a strong academic research environment offered by NSU. Through this critical merger RGI has gained greater access to new ideas, talented scientists, motivated students and cutting-edge technologies. The merger has enabled wider collaborations in both basic and translational research, and an increase in the total value of cancer research being conducted at RGI. For many, this re-joining of RGI and NSU was a homecoming since RGI was originally established in 1969 on the campus of a small, relatively young institution of higher education in Davie, Florida that was called NOVA at that time. Today that institution has transformed into Nova Southeastern University, which has grown to become the eighth largest non-profit independent university in the nation with more than 25,000 students.
Achievements of RGI at NSU
With industrial and academic partners, RGI is committed to developing anti-cancer therapies using efficient cancer growth and metastasis models aimed at moving novel compounds to market quickly. It is investigating why cancer resists chemotherapy, how resistance can be overcome, which chemotherapeutic agents most likely will work in an individual, and what causes cancer to spread. RGI aims to develop therapies targeting tumors, with minimal cellular damage and toxicity. Long relationship with the National Cancer Institute (NCI) and National Institutes of Health support promising investigational therapies.
RGI is steadily advancing research projects toward discovering additional treatments for breast, prostate, colorectal, and lung cancer using complementary medicine. Projects to characterize molecular mechanisms involved in controlling angiogenesis and cancer metastasis are making steady strides and could attract funds from the National Cancer Institute.
Collaborating with Lombardi Cancer Center of Georgetown University, RGI recently discovered an important anti-cancer drug. Code named JFD, this drug was one of several drug molecules identified using molecular modeling through sophisticated virtual screening technology. JFD is expected to produce an anti-cancer effect through anti-angiogenesis mechanisms. When administered to mice with breast cancer tumors, JFD produced amazingly efficient control of cancer growth and tumor reduction in 21 days compared to the drug of choice since 1970. NSU has applied for a patent for anti-cancer use of JSD to treat breast, prostrate, and lung cancers.
RGI is continuing its research and anticancer drug screening emphasizing its unique human zenograft model and cell line derivative as recognized by NCI and academia. Its future home will be at the world–class Center for Collaborative Research to be built on the NSU campus.
Advances by RGI allow more people diagnosed with malignancies to become "survivors" instead of "victims".
The Royal Dames of Cancer Research, Inc. are proud to be part of the exciting and productive partnership of NSU and RGI. Through our collective efforts, scientific projects will continue to foster ground–breaking success in keeping cancer survival on the rise.